WuXi Bi­o­log­ics IPO reaps $509M wind­fall; In­tel­lia strikes CRISPR pact with San Raf­faele

→  WuXi Bi­o­log­ics raised HK$3.8 bil­lion ($509 mil­lion) as it had set its sights on last month, of­fer­ing 193 mil­lion shares at HK$20.60 ($2.64). The Wuxi, Chi­na-based com­pa­ny will list on the Hong Kong Ex­change. Bo­fA Mer­rill Lynch, Mor­gan Stan­ley and Chi­na Mer­chants Se­cu­ri­ties are the joint bookrun­ners on the deal which is ex­pect­ed to price June 6, 2017.

→  Cam­bridge, Mass-based In­tel­lia has part­nered with San Raf­faele Uni­ver­si­ty in Italy. The two en­tered a three-year agree­ment to col­lab­o­rate on re­search us­ing In­tel­lia’s CRISPR/Cas9 genome edit­ing tech­niques to en­gi­neer new T Cell ther­a­pies to fight can­cer. In­tel­lia has been op­ti­miz­ing its gene edit­ing sys­tem in pre­clin­i­cal tri­als in hopes of de­vel­op­ing the ac­cu­ra­cy to cre­ate a one-time cure for dis­eases. This is the first ex­ter­nal part­ner­ship of the eX­tel­lia di­vi­sion.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN